KRAS and lung adenocarcinoma: Basically, mutations involving EGFR, ERBB2 and KRAS are mutually exclusive and are thought to represent early events in the carcinogenesis of lung adenocarcinoma in never (EGFR and ERBB2) and current smokers (KRAS) [23].